| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2009: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2008: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2007: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Research Abstract |
Diagnostic performance and value of ^<18>F-FAMT PET was examined to verify clinical implication in patients with non-small cell lung cancer (NSCLC). Specificity of ^<18>F-FAMT PET was superior to ^<18>F-FDG PET. The uptake of ^<18>F-FAMT was correlated with LAT1 expression as well as cellular proliferation and VEGF expression. Patients with positive LAT1 had significantly shorter 5-year survival as compared with negative LAT1. LAT1, as well as pathological stage and CD98 expression, was an independent prognostic factor, indicating diagnostic and prognostic value of ^18<F>-FAMT PET in NSCLC.
|
